Completed PHASE4 INTERVENTIONAL 2-arm NCT02675322

Danlou Tablets to Prevent Left Ventricular Remodeling

Effects of Danlou Tablets to Prevent Left Ventricular Remodeling After Myocardial Infarction: A Double-blind, Randomized, Placebo Controlled, Pilot Study

Sponsor: shuai Mao

Conditions Acute Myocardial Infarction Left Ventricular Remodeling

Interventions Danlou Tablets Placebo

Updated 5 times since 2017 Last updated: Feb 4, 2016 Started: Jan 31, 2012 Primary completion: Jan 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Myocardial Infarction and Left Ventricular Remodeling and is currently completed. shuai Mao leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

shuai Mao

Data source: Guangdong Provincial Hospital of Traditional Chinese Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.